Imiquimod cream is a prescription topical medication that treats three main conditions: genital and perianal warts, certain precancerous skin spots called actinic keratoses, and a type of skin cancer called superficial basal cell carcinoma. Sold under the brand name Aldara, it works differently from most skin treatments because it doesn’t attack the problem directly. Instead, it activates your immune system to do the work.
How Imiquimod Works
Most topical creams either kill cells or block their growth. Imiquimod takes a different approach. It triggers a specific receptor on immune cells in your skin, essentially sounding an alarm that draws your body’s defenses to the treated area. Those immune cells then release a cascade of inflammatory signals that help your body recognize and destroy abnormal cells, whether they’re virus-infected or precancerous.
This immune activation is why the cream causes visible inflammation at the treatment site. The redness, swelling, and irritation aren’t side effects in the traditional sense. They’re signs the cream is working. Your skin mounts a localized immune response, and that response is what clears the targeted cells.
Genital and Perianal Warts
External genital and perianal warts, caused by certain strains of HPV, are the most well-known use for imiquimod. The cream is approved for patients 12 and older with a healthy immune system. You apply a thin layer to the warts, typically three times per week, leaving it on overnight and washing it off in the morning. Treatment continues until the warts clear or for up to 16 weeks.
Because imiquimod stimulates your immune system rather than burning or freezing the warts off, it can sometimes take several weeks before you notice changes. The warts may become inflamed and irritated before they begin to shrink and eventually disappear. This gradual process is normal and reflects the immune response building over time.
Actinic Keratoses
Actinic keratoses are rough, scaly patches caused by years of sun exposure, most commonly found on the face and scalp. They’re considered precancerous because a small percentage can develop into squamous cell carcinoma if left untreated. Imiquimod is approved for flat, non-thickened actinic keratoses on the face or scalp in adults with healthy immune systems.
For this condition, the cream is typically applied two times per week to a defined treatment area for 16 weeks. The treatment area may look significantly worse before it looks better, with redness, crusting, and peeling as the immune system targets damaged skin cells. A rest period may be built into the schedule to let the skin recover partway through. After treatment ends, a follow-up assessment determines whether the spots have cleared or if additional treatment is needed.
The advantage of imiquimod for actinic keratoses is that it can treat an entire field of sun-damaged skin at once, rather than targeting individual spots one at a time, as freezing with liquid nitrogen does. This “field treatment” approach can address both visible spots and invisible precancerous changes in the surrounding skin.
Superficial Basal Cell Carcinoma
Imiquimod is also approved to treat a specific type of skin cancer: primary superficial basal cell carcinoma. This is the least aggressive form of basal cell carcinoma, growing only in the top layer of skin. The cream is approved for tumors no larger than 2 centimeters, located on the trunk, neck, or limbs (not the hands, feet, or genital area), and only when surgery isn’t the best option for the patient.
For superficial basal cell carcinoma, the cream is applied five times per week for six weeks. In clinical trials, this regimen produced a short-term success rate of about 87%. A large trial published in The Lancet Oncology compared imiquimod to surgical removal and found that at three years, 84% of patients treated with imiquimod remained clear compared to 98% in the surgery group. Surgery is more effective, which is why imiquimod is positioned as an alternative when surgery isn’t ideal, for example in patients with multiple lesions, those who can’t tolerate surgery, or when the tumor is in a location where scarring is a concern.
Off-Label Uses
Dermatologists sometimes prescribe imiquimod for conditions beyond its three approved uses. Molluscum contagiosum, a viral skin infection that causes small, dome-shaped bumps, is one of the more common off-label applications. This is particularly useful for patients with widespread molluscum where treating each bump individually would be impractical. The cream has also been studied for common warts on the hands and feet, though results for those tend to be less consistent than for genital warts.
What the Skin Reaction Looks Like
The most important thing to understand about imiquimod is that it will make your skin look worse before it looks better. In clinical studies, 93% of patients experienced redness at the treatment site, and 28% had severe redness at some point during treatment. About two-thirds of patients developed some degree of scabbing or crusting, and roughly the same proportion experienced flaking and dryness.
Swelling is also common, affecting about 63% of patients to some degree. Erosion or shallow ulceration occurred in about a third of patients, though severe erosion was rare at around 2%. Weeping or oozing from the treated area happened in about 15% of patients.
These reactions typically build over the first few weeks of treatment. Based on what’s known about the inflammatory timeline, skin inflammation tends to peak around the first week or two of consistent use, then gradually subsides after treatment stops. Most skin returns to normal appearance within a few weeks of finishing the course, though the timeline varies depending on the condition being treated and how long the treatment lasted.
Who Should Be Cautious
Imiquimod is designed for people with normally functioning immune systems. If your immune system is suppressed, whether from medication, an organ transplant, or a condition like HIV, the cream may not work as intended because it relies on your body’s own immune response.
People with autoimmune conditions should use imiquimod with caution, as ramping up immune activity in the skin could potentially trigger or worsen autoimmune flares. The cream can also aggravate existing inflammatory skin conditions. Its safety during pregnancy hasn’t been established in human studies, and it’s unknown whether it passes into breast milk when applied to the skin.
The cream should only be applied to the skin surface. It’s not for use inside the vagina, urethra, or on open wounds. Treated skin should be protected from sunlight, as the inflammatory response can make the area more vulnerable to sun damage.